| HOME >> BIOLOGY >> TECHNOLOGY |
MOUNTAIN VIEW, Calif., Feb. 12 /PRNewswire/ -- iZumi Bio, Inc., announced today the appointment of John P. Walker as Chief Executive Officer and a member of the company's Board of Directors. Walker was most recently the Chairman and CEO of Novacea, Inc. which merged with Transcept Pharmaceuticals Inc. in January 2009.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080806/AQW065LOGO)
iZumi Bio is focused on the development of induced pluripotent stem (iPS) cell technology to transform drug discovery and enable the promise of regenerative medicine.
"This is an exceptionally exciting time to be joining iZumi Bio, as we are seeing an increasing interest in the promise of stem cells to transform many aspects of the pharmaceutical industry," said Walker. "iZumi Bio has a leading position in industrializing the potential of iPS cells. Our goal is to create fully annotated, disease specific human cell lines that will fundamentally change the way in which small molecule drug discovery and development will be conducted in the future."
He continued, "Additionally, the development of these differentiated cell lines will enable the development of patient specific and cell replacement therapies."
Prior to joining Novacea, Walker, serving as a consultant and investor, was Executive Chairman and Principal Executive Officer of Renovis Inc.; Chairman and Interim CEO of Guava Technologies; KAI Pharmaceuticals and Centaur Pharmaceuticals; and Chairman and CEO of Bayhill Therapeutics. From 1993 to 2001, he was Chairman and CEO of Arris Pharmaceuticals and its successor corporation AXYS Pharmaceuticals Inc., and previously was Chairman and CEO of Vitaphore Corporation.
Walker began his career with American Hospital Supply Corporation, where
he last served as President of the American Hosp
'/>"/>
| SOURCE iZumi Bio, Inc. Copyright©2009 PR Newswire. All rights reserved |